Literature DB >> 19272197

Estimating hepatitis C infection acquired in England, 1986-2000.

M A Balogun1, A J Vyse, L M Hesketh, G Kafatos, J V Parry, M E Ramsay.   

Abstract

Hepatitis C is a global health problem and in the UK seroprevalence studies have mainly concentrated on specific high-risk groups. The aim of this study was to determine changes in the prevalence of antibody to hepatitis C virus in England using residual specimens collected between 1986 and 2000 reflecting the general population. A cross-sectional study design using a convenience collection of serum specimens from adult patients submitted to laboratories in the years 1986, 1991, 1996 and 2000 from a total of 19 laboratories around England were investigated. The main outcome was to determine anti-HCV prevalence and the average incidence occurring between 1986 and 2000 and factors associated with infection. Multivariable analysis of results from all years showed there was a significant difference in prevalence between males and females (P < 0.001), birth cohort (P < 0.001) and by health region (P < 0.001). An average of 0.72% (95% CI 0-1.65%) of those susceptible to HCV born between 1950 and 1970 were estimated to have acquired the infection between 1986 and 2000. Analysis of this convenience serum collection suggests that HCV prevalence is low in the general population, and is associated with period of birth, gender and health region. There was evidence to support a low incidence of HCV infection in those born between 1950 and 1970 over the period 1986-2000 which, at the population level, equated to a substantial burden of infection (approximately 106,000 persons). Continued surveillance and prevention targeted at injecting drug users are essential for the control of hepatitis C in the UK.

Entities:  

Mesh:

Year:  2009        PMID: 19272197     DOI: 10.1017/S0950268809002143

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  4 in total

1.  Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases.

Authors:  Sabra L Klein
Journal:  Bioessays       Date:  2012-09-26       Impact factor: 4.345

2.  Systematic analysis of funding awarded for viral hepatitis-related research to institutions in the United Kingdom, 1997-2010.

Authors:  M G Head; J R Fitchett; G S Cooke; G R Foster; R Atun
Journal:  J Viral Hepat       Date:  2014-08-22       Impact factor: 3.728

Review 3.  Sex Differences in Immunity to Viral Infections.

Authors:  Henning Jacobsen; Sabra L Klein
Journal:  Front Immunol       Date:  2021-08-31       Impact factor: 7.561

4.  Alzheimer's disease-related transcriptional sex differences in myeloid cells.

Authors:  Isabelle Coales; Stergios Tsartsalis; David Owen; Paul M Matthews; Nurun Fancy; Maria Weinert; Daniel Clode
Journal:  J Neuroinflammation       Date:  2022-10-05       Impact factor: 9.587

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.